Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Oblimersen may increase the effectiveness of dexamethasone by
making cancer cells more sensitive to the drug. It is not yet known if dexamethasone is more
effective with or without oblimersen in treating multiple myeloma.
PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with or
without oblimersen in treating patients who have relapsed or refractory multiple myeloma.